John T Cavan
CIK 1503738 · Chief Financial Officer · last filed 2021-05-20
John T Cavan is a Chief Financial Officer who has filed 12 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for HEPA, was dated May 20, 2021. Across all open-market trades the lifetime net is +$40.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.2K
2
12
$40.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HEPA | Chief Financial Officer | 14,800 | $0.08 | $1.2K | $27.3K | 6 | 2021-05-20 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | CFO | 167,947 | — | — | $13.0K | 6 | 2018-07-03 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-05-20 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2021-02-18 | HEPA | Buy (P) | +10,000 | $20.0K | EDGAR |
| 2020-11-30 | HEPA | Buy (P) | +4,500 | $7.3K | EDGAR |
| 2020-08-21 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2020-04-07 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2019-07-25 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Buy (P) | — | $0 | EDGAR |
| 2018-01-05 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Grant (A) | +101,221 | $0 | EDGAR |
| 2017-07-21 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-07 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Grant (A) | +46,726 | $0 | EDGAR |